| CAS 登记号 | 471905-41-6 |
| 分子式 | C21H21ClF2O4S |
| 分子量 (MW) | 443.0 g/mol |
| EINECS 编号 | -- |
| 中文别名 | 顺式-4-[(4-氯苯基)磺酰基]-4-(2,5-二氟苯基)环己烷丙酸, 一种适度有效的Γ-SECRETASE(Γ-分泌酶)抑制剂;顺式-4-[(4-氯苯基)磺酰基]-4-(2,5-二氟苯基)环己烷丙酸 |
| 规范 SMILES | C1CC(CCC1CCC(=O)O)(C2=C(C=CC(=C2)F)F)S(=O)(=O)C3=CC=C(C=C3)Cl |
| InChIKey | XCGJIFAKUZNNOR-UHFFFAOYSA-N |
| 主要用途与行业 |
生物活性 MK-0752是一种适度有效的γ-secretase(γ-分泌酶)抑制剂,降低Aβ40产量,IC50为5 nM。Phase 1/2...
查看详细工业用途与工艺规范
|
生物活性 MK-0752是一种适度有效的γ-secretase(γ-分泌酶)抑制剂,降低Aβ40产量,IC50为5 nM。Phase 1/2。体外研究 MK-0752 is identified as a moderately potent γ-secretase inhibitor, which reduces Aβ40 in a dose-dependent manner with an IC50 of 5 nM in human SH-SY5Y cells. In vitro, MK-0752 blocks Notch-intracellular domain (ICD) cleavage and its subsequent nuclear translocation. 体内研究 MK-0752 (240 mg/kg) reduces the generation of newly produced Aβ with 90% decrease of AUV in the brain of rhesus monkeys. In addition, MK-0752 treatment increases levels of Aβ 1-14, Aβ 1-15, and Aβ 1-16 , while decreases levels of Aβ 1-17. In guinea-pigs, oral administration of MK-0752 (10 mg/kg -30 mg/kg) results in the dose-dependent reduction of Aβ40 in plasma, brain and cerebrospinal fluid (CSF) with IC50 of 440 nM in brain. 特征 MK-0752 is a moderately potent γ-secretase inhibitor.。
